Lexicon Appoints Ivan H. Cheung to Board of Directors

Core Insights - Lexicon Pharmaceuticals has elected Ivan H. Cheung to its Board of Directors, marking a significant moment in the company's history [1][4] - Mr. Cheung brings over 25 years of experience in the healthcare industry and has a strong track record in shareholder value creation [2][3] - The appointment coincides with the retirement of Robert J. Lefkowitz, who served on the board for 23 years [4][5] Company Overview - Lexicon Pharmaceuticals is focused on pioneering medicines that transform patients' lives, utilizing its Genome5000™ program to study nearly 5,000 genes and identify over 100 protein targets with therapeutic potential [5] - The company has commercially launched INPEFA® (sotagliflozin) in the United States and has a pipeline of drug candidates in various stages of development for conditions such as neuropathic pain, diabetes, and metabolism [5]